大剂量异环磷酰胺治疗肝细胞癌的II期研究。

Phase II study of high-dose ifosfamide in hepatocellular carcinoma.

作者信息

Lin J, Shiu W, Leung W T, Tao M, Leung N, Lau W Y, Li A K

机构信息

Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin.

出版信息

Cancer Chemother Pharmacol. 1993;31(4):338-9. doi: 10.1007/BF00685682.

DOI:10.1007/BF00685682

PMID:8380759

Abstract

A phase II study of high-dose ifosfamide in hepatocellular carcinoma was conducted among 17 Chinese patients. The dose of ifosfamide used was 2.5 g/m2 daily given as a continuous infusion for 5 days. In all, 15 patients were evaluable for tumour response. There was no complete or partial responder. The treatment was well tolerated. The most frequent toxicity was alopecia, which occurred in 11 patients, and 5 patients developed mild haematological toxicity. There was no evidence of liver or bladder toxicity. Overall, 14 patients were evaluable for survival. The median survival was 92 days (range, 30-568 days). We conclude that high-dose ifosfamide is well tolerated but ineffective in hepatocellular carcinoma in Chinese patients.

摘要

一项针对17名中国患者开展的高剂量异环磷酰胺治疗肝细胞癌的II期研究。所使用的异环磷酰胺剂量为每日2.5 g/m²，持续静脉输注5天。总计15名患者可评估肿瘤反应。无完全缓解或部分缓解者。该治疗耐受性良好。最常见的毒性反应是脱发，11名患者出现脱发，5名患者出现轻度血液学毒性。无肝脏或膀胱毒性证据。总体而言，14名患者可评估生存情况。中位生存期为92天（范围30 - 568天）。我们得出结论，高剂量异环磷酰胺在中国患者的肝细胞癌治疗中耐受性良好但无效。